Advertisement

Ads Placeholder
Loading...

Incannex Healthcare Limited

IHL.AXASX
Healthcare
Drug Manufacturers - Specialty & Generic
$0.04
$-0.00(-10.87%)
Australian Market is Open • 15:05

Incannex Healthcare Limited Fundamental Analysis

Incannex Healthcare Limited (IHL.AX) shows weak financial fundamentals with a PE ratio of -3.15, profit margin of -19.71%, and ROE of -33.30%. The company generates $0.0B in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

Cash Position52.95%
PEG Ratio-0.03
Current Ratio9.02

Areas of Concern

ROE-33.30%
Operating Margin-17.47%
We analyze IHL.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1481.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1481.4/100

We analyze IHL.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

IHL.AX struggles to generate sufficient returns from assets.

ROA > 10%
-22.55%

Valuation Score

Excellent

IHL.AX trades at attractive valuation levels.

PE < 25
-3.15
PEG Ratio < 2
-0.03

Growth Score

Moderate

IHL.AX shows steady but slowing expansion.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
64.04%

Financial Health Score

Excellent

IHL.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.01
Current Ratio > 1
9.02

Profitability Score

Weak

IHL.AX struggles to sustain strong margins.

ROE > 15%
-3329.98%
Net Margin ≥ 15%
-19.71%
Positive Free Cash Flow
No

Key Financial Metrics

Is IHL.AX Expensive or Cheap?

P/E Ratio

IHL.AX trades at -3.15 times earnings. This suggests potential undervaluation.

-3.15

PEG Ratio

When adjusting for growth, IHL.AX's PEG of -0.03 indicates potential undervaluation.

-0.03

Price to Book

The market values Incannex Healthcare Limited at 0.75 times its book value. This may indicate undervaluation.

0.75

EV/EBITDA

Enterprise value stands at -2.65 times EBITDA. This is generally considered low.

-2.65

How Well Does IHL.AX Make Money?

Net Profit Margin

For every $100 in sales, Incannex Healthcare Limited keeps $-19.71 as profit after all expenses.

-19.71%

Operating Margin

Core operations generate -17.47 in profit for every $100 in revenue, before interest and taxes.

-17.47%

ROE

Management delivers $-33.30 in profit for every $100 of shareholder equity.

-33.30%

ROA

Incannex Healthcare Limited generates $-22.55 in profit for every $100 in assets, demonstrating efficient asset deployment.

-22.55%

Following the Money - Real Cash Generation

Operating Cash Flow

Incannex Healthcare Limited generates limited operating cash flow of $-3.61M, signaling weaker underlying cash strength.

$-3.61M

Free Cash Flow

Incannex Healthcare Limited generates weak or negative free cash flow of $-3.71M, restricting financial flexibility.

$-3.71M

FCF Per Share

Each share generates $-0.01 in free cash annually.

$-0.01

FCF Yield

IHL.AX converts -1.15% of its market value into free cash.

-1.15%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.15

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.03

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.75

vs 25 benchmark

P/S Ratio

Price to sales ratio

14.06

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.009

vs 25 benchmark

Current Ratio

Current assets to current liabilities

9.02

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.33

vs 25 benchmark

ROA

Return on assets percentage

-0.23

vs 25 benchmark

ROCE

Return on capital employed

-0.21

vs 25 benchmark

How IHL.AX Stacks Against Its Sector Peers

MetricIHL.AX ValueSector AveragePerformance
P/E Ratio-3.1528.54 Better (Cheaper)
ROE-33.30%738.00% Weak
Net Margin-1970.61%-43982.00% (disorted) Weak
Debt/Equity0.010.34 Strong (Low Leverage)
Current Ratio9.022806.01 Strong Liquidity
ROA-22.55%-14624.00% (disorted) Weak

IHL.AX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Incannex Healthcare Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

7516.54%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-6593.35%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-7129.36%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ